ライフサイエンスコーパス: median age

1 was measured in contrast SB series (n = 169, median age 0.94, range 0.32-2.7 years) during 2002 to 20

2 riteria, 2429 were included in the analysis (median age, 10 years; interquartile range, 8-13 years; 1

3 the 920 children (444 females and 476 males; median age, 11.4 years [interquartile range, 11.1-11.8 y

4 d 52 children with DCM who underwent CPET at median age 12.6 years (interquartile range [IQR], 9.9-14

5 Thirty-four patients (17 males; median age, 12.2 y; age range, 6.8-19.1 y) underwent PET

6 nd ascending and sigmoid colons of children (median age 13 years) newly diagnosed with IBD (43 with C

7 and 56 to the metronomic chemotherapy group (median age, 13 years; 42 male [75.0%]).

8 mages of the knee in 151 children, 73 girls (median age, 14.1 years; range, 6.5-17.8 years) and 78 bo

9 Seventy-nine patients (64%) responded (median age 15, range 4-32 years; 86% rectosigmoid agangl

10 ed, with 52 randomized to the placebo group (median age, 15 years; 40 male [76.9%]) and 56 to the met

11 Eighteen patients (11 male; median age, 15.2 y; age range, 9.5-22.6 y) comprised the

12 We included 54 patients (median age, 15.5 years; 25 months of follow-up; 30 seizu

13 Of 14 patients (7 males and 7 females; median age, 16 years [interquartile range, 15.0-22.5 yea

14 1 years; range, 6.5-17.8 years) and 78 boys (median age, 16.6 years; range, 6.9-17.9 years), studied

15 We enrolled 253 infants (median age 2.1 [25%-75% interquartile range] months).

16 Ten patients (median age 2.71 years, IQR 2.46-6.35) were enrolled from

17 was completed in 56 eyes; 43 were analyzed (median age, 2.4 months; range, 1.0-6.8 months).

18 There were 101 participants, median age 20 years (range 15 to 22).

19 regular cannabis users (24 men and 4 women; median age, 22 years [95% CI, 21-24 years]), and the rem

20 Ninety-seven patients with stable asthma (median age, 23 years [interquartile range, 21-27 years];

21 Among 205 participants (54% female, median age 24 years), epileptiform discharges were detec

22 aining 24 were controls (20 men and 4 women; median age, 24 years [95% CI, 23-27 years]).

23 Sixty healthy volunteers (median age, 26 y; 42% female) were given the NSAID diclo

24 for 5 or more years after initial diagnosis (median age, 27 years; range, 18 to 48 years), treated fr

25 The study included 9410 women (median age, 27.0 [interquartile range, 9.0] years; 60.7%

26 In the cohort (median age, 28 years; median pre-ART VL, 3.99 copies/mL;

27 Of the 777 infants included in the study (median age, 3 months; interquartile range, 2-5 months; 4

28 Thirty-nine adults after TBI (84.6% male, median age = 30.5 years, 87.2% moderate-severe, median t

29 hort 1 (50 women [69.4%] and 22 men [30.6%]; median age, 31.0 years [IQR, 26.3-38.3 years]), with sho

30 Of 1470 women (median age 33 years), 357 (24%) had bacterial vaginosis

31 In total, 595 patients were included (median age, 33 years; interquartile range, 25-41 years;

32 5 eligible participants who were randomized (median age, 34 years [interquartile range, 26.0-45.5 yea

33 ort 2 (162 women [67.5%] and 78 men [32.5%]; median age, 34.0 years [IQR, 29.0-42.0 years]) consistin

34 rican Indian men and women free of diabetes (median age, 36 y).

35 with myotonic dystrophy type 1 (women, 51%; median age, 37 years), with genetic testing performed at

36 Among 937 adults (median age, 37 years; 66.5% were male), patients with se

37 ars]; 60% female) and 47 healthy volunteers (median age, 38 years [interquartile range, 29-47 years];

38 617 adult patients with Ph-negative BCP-ALL (median age, 38 years), treated in the intensified Group

39 % of the patients (85% of cases were female, median age, 38 years); 7% of the nodules were borderline

40 Among 3886 women (median age, 38 years; interquartile range [IQR], 30-46 y

41 for the breast cancer analysis, 5066 women (median age, 38 years; IQR, 31-47 years) eligible for the

42 viduals in our study population (49% female; median age, 39 y), 787 (7.0%) reported having tanned ind

43 Of the 765130 adults (median age, 39 years; interquartile range, 29-49 years;

44 IS, 55 with PVI, and 77 controls (male, 53%; median age, 4.8 years).

45 In the 16 patients (6 men and 10 women; median age, 42 [range, 18-69] years), clinical improveme

46 9 years; age range, 5-93 years; and 13 male; median age, 42 years; age range, 4-76 years) was mainly

47 ong the 189289 patients included (54% women; median age, 43 years [interquartile range, 32-56 years])

48 previously healthy control subjects (14 men; median age, 43 years; interquartile range, 18 years) und

49 patients were identified (female, 42 [80%]; median age, 44 years; age range, 13-82 years).

50 Seventeen men (11 Hispanic, 6 white, median age 45 years) were enrolled.

51 c diagnosis of systemic sarcoidosis (21 men; median age, 45 years; interquartile range, 22 years) and

52 er 87 months were included; 68% were female, median age 46 (range, 11-88 years), and median presentin

53 the ovarian cancer analysis, and 2213 women (median age, 47 years; IQR, 40-55 years) eligible for the

54 diagnosis of syncope were identified, with a median age 48.4 years (first to third quartiles, 33.0-59

55 Among 571 patients (median age, 49 years [interquartile range, 43-55 years];

56 trate from the 33 study patients (20 female; median age, 49 years; age range, 5-93 years; and 13 male

57 ndividuals without AF diagnosis at baseline (median age, 49.6 years; age range, 24.1-97.6 years; 51.7

58 The analysis included 527 patients (median age, 51 [range, 23-84] years).

59 o 2013, 2561 white participants (1336 women; median age, 52 years; 25th and 75th quartiles, 42 and 62

60 293 patients (median age 55 years [IQR 45.0-65.5]) were included in th

61 Among 891 women who were randomized (median age, 55 years), 856 (96%) completed the trial (44

62 f follow-up, 602 cancer cases were observed (median age, 55.4 years).

63 tudy included a final sample of 20 patients (median age, 55.5 years [range, 22-74 years]; 15 [75%] fe

64 patients with active HCV-associated CryoVas (median age, 56 y; 53.6% women) were recruited from hospi

65 Of 320 patients randomized (268 [84%] male; median age, 56 years), 156 received arm A and 159 arm B.

66 All 5999 participants (median age, 56 years; women, 61.9%) were included in the

67 d the following characteristics: 78% female; median age 58 years; median AMA titer 1:160; extrahepati

68 Fifty-two women with metaplastic TNBC (median age, 58 years; range, 37-79 years) were treated w

69 h DG (37.7% male; 9.9% with type 1 diabetes; median age, 58.2 years [range 20-76]; median body mass i

70 vational studies), involving 62068 patients (median age, 58.8 years; median APACHE [Acute Physiology

71 Patients with Q waves were older (median age, 59 versus 57), were more often male (82.0% v

72 epatic resection (46.8% men and 53.2% women; median age, 59 years [interquartile range, 49-69 years])

73 Among 1137 patients (median age, 59 years; 440 [39%] women), 1074 (94%) of pa

74 Our SDS cohort was young (median age 6.3 years), and many of the patients had mult

75 In the remaining 707 children (65.1% girls; median age, 6.2 years), 645 were diagnosed with celiac d

76 Screened patients were slightly older (median age, 60 vs 57 years; P < .001) but did not differ

77 Of the 98999 women (median age, 60 years [interquartile range, 50-71 years])

78 interstitial pneumonia (men, 79; women, 165; median age, 60.5 years [range, 23-86 years]), and 192 wi

79 Of 4759 participants (median age 61.3 years, 55.2% women) with a median follow

80 he 70124 patients with positive FIT results (median age, 61 years [IQR, 55-67 years]; men, 52.7%), th

81 ormed on 4772 participants (2868 men, 49.9%; median age, 61 years) performed at 3 institutions, witho

82 spective analysis of 92 patients with HGSOC (median age, 61 years) with abdominopelvic CT before prim

83 Our analyses included 5433 participants (median age, 61 years; 49.7% male) with 2 colonoscopies (

84 1 studies in the cisplatin-etoposide groups (median age, 61 years; 65% male; 40% squamous histology;

85 ic cancer 5 cm or smaller (13 women, 12 men; median age, 61 years; age range, 41-78 years) were prosp

86 ents (253 men [55.1%] and 206 women [44.9%]; median age, 62 years [interquartile range, 46-75 years])

87 40 patients approached, 303 (89%) consented (median age, 62 years [interquartile range, 53-71]; 57% m

88 6 randomized patients (39% [n = 203] female; median age, 62 years [range, 18-90 years]), 306 (58%) ex

89 83 with microsatellite stability or low MSI [median age, 62 years; 219 males (77.4%)] and 20 with hig

90 ctal surgery patients in an established ERP (median age 63, 57% male, 80% laparoscopic) randomized 1:

91 eiden Longevity Study (N = 661; 50.5% women, median age 63.1 years), facial skin aging features (perc

92 The trial reached its accrual goal of 42 median age, 63 years (range, 45-83 years); male, 28 (67%

93 ed stopping the study for futility when 894 (median age, 63 years; 286 [32%] women) of the planned 11

94 Among 225 randomized participants (median age, 63 years; 36% women) 203 completed the study

95 48 studies in carboplatin-paclitaxel groups (median age, 63 years; 65% male; 40% squamous histology;

96 selected patients with and without delirium (median age, 63 yr; range, 23-84) who were assessed with

97 METHODS AND Seventy patients (median age, 63.5 years) with persistent atrial fibrillat

98 a median of 3 (range: 2-5) lines of therapy, median age 64 (range: 35-83) years, and had received bot

99 A total of 30 patients (median age 64 years, 73% male, 30% ischemic pathogenesis

100 reatic resection (50.8% men and 49.2% women; median age, 65 years [interquartile range, 55-73 years])

101 Among 1822 patients who were randomized (median age, 65 years; 980 [53.8%] women; 855 with breast

102 l of 881 patients participated in the study (median age, 65 years; age range, 41-80 years; 633 white

103 the Rotterdam Study (N = 3,831; 58.2% women, median age 66.5 years) and Leiden Longevity Study (N = 6

104 ensitivity pneumonitis (men, 76; women, 116; median age, 66 years [range, 35-88 years]).

105 rs; 219 males (77.4%)] and 20 with high MSI [median age, 66 years; 14 males (70.0%)]).

106 four admissions of mixed adult ICU patients (median age, 66.0 yr [interquartile range, 54.0-74.0]; Ac

107 Blood was drawn from 12 male CCI patients (median age 67 y, range 48-79 y) receiving continuous mec

108 nd March 31, 2014, we enrolled 261 patients (median age 68 years [IQR 61-74], median previous therapi

109 nrolled and all patients received treatment; median age 68 years.

110 A total of 298 patients were accrued (median age, 68.8 [range, 32-94] years at day 10 and 68.0

111 Among 98 randomized patients, 94 (96%) (median age, 68.8 years [interquartile range, 61.2-75.3 y

112 The IVUS group was younger (median age, 70 versus 75 years) and had fewer comorbidit

113 hundred forty-five eyes of 769 participants (median age, 70 years [range, 42-90 years], 60.8% women,

114 andomly sampled from the general population (median age, 70 years; 63% male).

115 Among 258 patients offered screening (median age, 70 years; age range, 35-94 years; 255 [98.8%

116 Overall, 462 cases were included (median age 72 years, 50% men).

117 There were 52 ALRI hospitalizations (median age, 72 days).

118 lmonary fibrosis (IPF) (men, 366; women, 90; median age, 72 years [range, 38-93 years]), 244 with non

119 d colon cancer were more likely to be older (median age, 73 vs 70 years; P < .001) and female (54.4%

120 A total of 131 patients (median age, 73 years [range, 26-89 years]) had intermedi

121 were 1293 men (61.8%) and 800 women (38.2%) (median age, 73 years).

122 Of 111 patients included (67 [60%] male; median age, 75 [range, 24-94] years), 81 (73%) were emer

123 8018 patients with NSTEMI 65 years or older (median age, 77 years [interquartile range, 71-84 years];

124 Among 284 students (median age, 8 years [interquartile range, 6-9 years]; 14

125 Forty-five patients (median age, 8.2 years; range 4.3-44) with FA underwent H

126 teral retinoblastoma (male patients, n = 14; median age, 8.4 months) received chemotherapy: two cours

127 patients with dementia and 733653 controls (median age, 80.3 years; interquartile range, 74.9-84.6 y

128 In a propensity-matched cohort (median age 82 years, 48% women, median Society of Thorac

129 ive patients with cancer, 2 men and 1 woman (median age, 83 years; range 77-91 years), experienced pe

130 nts in the study (11876 women and 11971 men; median age, 84 years [interquartile range, 78-88 years])

131 leaving 3036 patients included in the trial (median age, 85 [interquartile range, 81-89] years; 1361

132 ere included (age range = 5 days-33.4 years, median age = 9 years).

133 tudy (92 [50.8%] male and 89 female [49.2%]; median age, 9 years; age range, 0-65 years).

134 A total of 51 patients were recruited (median age, 9.6 years).

135 The median age and weight of the patients were 24 months {ra

136 ients (75 boys [70.1%] and 32 girls [29.9%]; median age at AIS, 7.7 years [interquartile range, 3.1-1

137 The median age at baseline of the 15 study participants was

138 We compared the median age at cancer diagnosis between PLWH in the North

139 We also compared median age at cancer diagnosis by AIDS status and CD4 co

140 Median age at cataract surgery was 2.2 months (interquar

141 Three boys (median age at death, 12 years; range, 9-13 years) who re

142 Among 202 deceased former football players (median age at death, 66 years [interquartile range, 47-7

143 athologically diagnosed in 177 players (87%; median age at death, 67 years [interquartile range, 52-7

144 Median age at diagnosis was 12 years and median follow-u

145 The median age at diagnosis was 41 years; 75% were male, and

146 Median age at diagnosis was 63 years, including 599 pati

147 Among survivors (median age at diagnosis, 62 years; 56% male), 115 were d

148 s assigned to systemic therapy) (77% female; median age at enrollment, 48 [interquartile range, 36-56

149 (1330 study eyes; 60.2% women and 39.8% men; median age at enrollment, 70 years [range, 42-90 years])

150 METHODS AND We included 3311 adults (median age at entry 22.6 years, 50.6% males) with CHD (4

151 Results Median age at evaluation was 37 years; median time since

152 ow-up of the subjects to substantially older median age at exit.

153 ants (21.4%) examined had eye abnormalities (median age at first eye examination, 31 days; range, 0-3

154 Of the 1471 children, the median age at first FS was 21 months (interquartile rang

155 Median age at genetic evaluation was 11 years; 20.7% of

156 The median age at HSCT was 7.5 years.

157 Sera from 35 children with proven CMA (median age at inclusion of 10 months) were analyzed retr

158 mong 7541 women with invasive breast cancer, median age at initial breast cancer diagnosis was 60.6 y

159 For this group of 14 patients, median age at initial diagnosis of Stargardt disease was

160 Among 5453 youths with type 1 diabetes (median age at initial diagnosis, 11 years; interquartile

161 2.6%]) and 7233 youths with type 2 diabetes (median age at initial diagnosis, 19 years; interquartile

162 s, 51% were male, 77% white persons, and the median age at last follow-up date was 11.5 years.

163 year or longer was associated with increased median age at loss of mobility milestones by 2.1-4.4 yea

164 Median age at onset of eye disease was 60 months and dur

165 Median age at referral was similar for men (22.5 years;

166 Of the 341 patients (175 men and 166 women; median age at study entry, 62 years) in the 1-year group

167 Results Median age at study was 6 years (range, 2 to 20 years);

168 Median age at surgery was 18.2 months (interquartile ran

169 The median age at surgery was 3.3 years (interquartile range

170 The median age at TA diagnosis was 36 [25-47] years, and 276

171 cific incidence and cumulative incidence and median age at the detection of strabismus, overall and b

172 We included 9 eyes; median age at the moment of the PPK was 14 years.

173 Their median age at the time of cladribine therapy was 62 year

174 276 women [34.2%]; 805 white [99.9%]) with a median age at the time of first staged excision procedur

175 pectively; 22 patients have become tolerant (median age at tolerance acquisition of 51 months) during

176 The median age at transplantation was 9 years, and the media

177 d and moderate hearing losses, for which the median age fell from 19 to 5 months.

178 The median age for patients with IBDI was 50.16 +/- 11.7 yea

179 The median age for the first infection was 9 (interquartile

180 The median age in the MFS group was 35.4 years versus 35.6 y

181 82 (47%) were men and 3637 (53%) were women; median age (interquartile range) for control and SSI cas

182 Participants had a median age of 12 months (range, 2-71 months) and 558 of

183 SSPE was diagnosed at a median age of 12 years (3-35 years), with a latency peri

184 y.We enrolled a total of 547 children with a median age of 13 mo at baseline.

185 We examined 13557 children at a median age of 16.2 years (48.5% were girls).

186 418 children (693 girls and 725 boys) with a median age of 27 months (interquartile range, 12-69 mont

187 In this survey, 774 adults with a median age of 30 +/- 14.33 years participated.

188 Men with Nm urethritis were a median age of 31 years (interquartile range [IQR] = 24-3

189 by the new criteria, 17 (47%) had CFLD at a median age of 36.6 years (interquartile range 26.5-43.2)

190 Results Median age of 42 girls and 18 boys was 3.3 years (range,

191 We included 34 patients with a median age of 46 years (40-54 yr); 65% were males.

192 38 patients (623 men and 2,015 women) with a median age of 46 years (interquartile range, 35 to 58 ye

193 A total of 246 patients were included with a median age of 47 years and 37% female.

194 The male to female ratio was 1:1.6 with median age of 48 years with interqurtile range of 20.

195 otal of 220 children (147 boys [67%]) with a median age of 5.0 months (interquartile range, 3.0-8.0 m

196 patients were included in the study, with a median age of 50 years (interquartile range, 44-57 years

197 Menopause occurs at a median age of 51.3 years, and the average US woman who r

198 cryptosporidiosis, mostly men (68%), with a median age of 52 (6-70) years old.

199 Patients had a median age of 52.3 years (interquartile range [IQR], 43.

200 Twenty glaucoma patients (60% women) with a median age of 54 years and mean deviation (MD) in the vi

201 articipate, 285 individuals enrolled, with a median age of 57 years (range, 24-88), 202 (74.3%) femal

202 B and 20 healthy controls (70% women) with a median age of 57 years and a mean MD of 0 dB were includ

203 ients were predominantly male (82.9%) with a median age of 58 years (53-62).

204 s included, 10 862 were men, with an overall median age of 59 years (range, 51-68 years).

205 The 362 analyzed patients (65% female) had a median age of 65 y (range, 19-96 y) and follow-up of 24

206 overy cohort was 53% male (n = 79) and had a median age of 67 (interquartile range, 58-74) years.

207 Overall, 32518 men with a median age of 67 years were diagnosed with favorable-ris

208 ation cohort was 50% male (n = 48) and had a median age of 68 (interquartile range, 60-75) years.

209 Sixty-three patients with a median age of 73 y who underwent 307 cycles of therapy w

210 Patients had a median age of 74 years and 42% were women.

211 rs (range, 71-101 years) and five men with a median age of 78 years (range, 70-88 years).

212 MA infants with 2 copies of SMN2 indicated a median age of 8 months at death (95% confidence interval

213 resh, unembalmed cadavers of 11 women with a median age of 85 years (range, 71-101 years) and five me

214 The median age of children was 4 months; 50.4% were female.

215 enesis was exacerbated by Trp53 co-deletion (median age of onset 275 days, penetrance 82% at 1 year),

216 three PPs facilitated melanoma development (median age of onset 308 days, penetrance 40% at 1 year).

217 Non-CLIPPERS patients' median age of onset was 52 years (interquartile range, 3

218 The median age of participants was 11 years (IQR 8-13) and 1

219 The median age of participants was 86 years (range, 48-96 ye

220 Median age of patients was 15 years (range 12-17).

221 The median age of patients was 15 years, and 75% had genotyp

222 Median age of patients was 29 years (IQR 20-44) and 715

223 The median age of patients was 84.6 years, and 49.7% were me

224 The median age of pediatric cases was 10 years (interquartil

225 The median age of recruited patients was 64 years of age, 43

226 The median age of subjects at presentation was 15 years (ran

227 of contemporary data from 2009 to 2013, the median age of survival in Canada was 10 years greater th

228 Median age of survival in patients with cystic fibrosis

229 In 2011, the median age of survival of patients with cystic fibrosis

230 The median age of the 1005 enrolled infants was 3 months (in

231 The median age of the graft at time of diagnosis was 42 year

232 ears) is projected at 33.5% in 2030, and the median age of the NAFLD population will increase from 50

233 The median age of the participants was 30 years; 36.6% of th

234 The median age of the participants was 50 years (interquarti

235 The median age of the patients was 53 years (range 37-64).

236 The median age of the patients was 66 years, and 72% were me

237 The median age of the remaining 1495 patients was 53 years a

238 Median age of the study cohort was 46 (interquartile ran

239 Median age of the study population was 40.0 years.

240 Median age of the study population was 63 years (range,

241 Median age of women was 26 years (IQR 21-37; range 18-52

242 The median ages of patients in the MI-ERR greater than 1 and

243 The median ages of those with and without a composite outcom

244 Median age was 1.9 years (IQR 0.8-4.8).

245 At study entry, median age was 11 months (interquartile range, 6-16 mont

246 The median age was 20 years (range 18-37 years).

247 Overall, the median age was 20 years lower for B(Victoria) vs B(Yamag

248 Across MSM sites (n = 11,997), the median age was 25 years and the median number of lifetim

249 Participants' median age was 28 years (IQR 24-32).

250 In the overall cohort, the median age was 29 years (interquartile range, 24-33 year

251 WID sites (n = 14,450), 92.4% were male, the median age was 30 years, and 87.5% reported injection in

252 The median age was 31 years (interquartile range, 19-44 year

253 tients included, 140 (96%) were male and the median age was 31 years.

254 ens from 459 people; 213 (46%) were men, the median age was 34 years (IQR: 27-44), and 130 (28%) were

255 patients analyzed (61 with HBV coinfection), median age was 35 years, 53.7% were women, and median ba

256 Median age was 36 years, 48% of participants were women,

257 Median age was 37 years, and median height was 1.71 m.

258 tients were female, 36% black, 13% Hispanic; median age was 37 years, CD4 count 321 cells/microL, and

259 Sixty-five percent were female; the median age was 37.4 years.

260 The median age was 39 y (age range, 19-69 y).

261 Median age was 41 years (interquartile range: 27 to 53 y

262 At baseline, the median age was 43 (interquartile range, 39-49), 85% were

263 Median age was 43 years, 88% were black, 73% male, 69% h

264 The median age was 43 years; 53% were female.

265 ric MDR-TB cases were female (n = 51 [62%]), median age was 5 years (interquartile range, 1-12 years)

266 Of 1015 participants, the median age was 51 years, 15% were aged >/=60 years, 19%

267 Results Median age was 52 years (range, 18 to 74 years) for HCT

268 ded in analysis, 4138 (54.7%) were male; the median age was 56 (range, 12-101) years.

269 Median age was 56 years (range, 18-69 years), and 95% ha

270 Their median age was 56 years (range, 29-81 years), and 48% we

271 itis (n = 8) or Barrett's esophagus (n = 6); median age was 56 years and median body mass index was 2

272 Of 1040 patients, the median age was 58 years (interquartile range, 50.5-66 ye

273 Of 863 patients, 551 (63.9%) were male and median age was 58 years (interquartile range, 51-68 year

274 In these patients, median age was 58 years (IQR 51-62), median number of pr

275 Median age was 58 years; 9 patients (43%) were transplan

276 Median age was 60 years (range, 18 to 91 years).

277 Median age was 61 years; 27% were women, 6% had cardiac

278 The median age was 63 years (interquartile range, 49-74), an

279 in the study, 11645 (76.2%) were men and the median age was 63 years (interquartile range, 56.6-70.7

280 The median age was 64 years, and 64% of patients were men.

281 Their median age was 65 years, 108 (43%) were female, and 161

282 of 360 patients were randomized, of whom the median age was 65 years, 129 (36%) were women, 200 (55.5

283 After propensity weighting, median age was 66 to 67 years across groups, and 77% to

284 Among 63 enrolled patients, median age was 66 years (range, 30-92).

285 The median age was 67 years, and the median PSA level was 53

286 the 27 patients, 26 (96%) were male and the median age was 67.8 years (interquartile range [IQR], 62

287 The median age was 68.0 years, and 29.5% had stage cT3/cT4 d

288 The median age was 69 years (interquartile range, 58-79 year

289 Median age was 69 years (interquartile range, 60-75 year

290 = 61933) of the patients were male, and the median age was 7 years (IQR, 1.9-12.3 years).

291 Of 122 children enrolled, the median age was 7 years and one-third were aged <5 years.

292 The median age was 70 years; 81% of patients were intermedia

293 The median age was 71 years (range, 25-102 years).

294 nts with CRKP colonization or infection, the median age was 73 years.

295 Median age was 74 years, and 37% of patients were women.

296 The median age was 75 years (interquartile range, 67-82), an

297 Median age was 77 years (range 62-92), and median follow

298 The median age was 78 years, and 73% (35/48) were male.

299 Median age was 82 years (interquartile range, 70-88).

300 Within the cohort of infants, the median age was 95 days, 90% received </=1 dose of vaccin